Quinazoline Compounds Selective NaV1.8 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sodium channel blockers for pain management lack selectivity, leading to undesirable side effects such as CNS and cardiovascular issues, and interact with other channels like hERG, Cytochrome P450, CaV1.2, and Kv1.5, necessitating the development of compounds with improved selectivity and reduced activity against these targets.
Innovation Solution
Development of specific compounds, such as those described by the formula I, which exhibit selective inhibition of sodium channels like NaV1.8 with minimal activity against NaV1.2, hERG, Cytochrome P450 isoforms, CaV1.2, and Kv1.5, enhancing pharmacokinetic and pharmacodynamic properties for improved therapeutic efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current sodium channel blockers are used for pain management, then pain relief is achieved, but selectivity is poor leading to CNS and cardiovascular side effects
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features (quinazoline core structure with particular substituents) that confer selective binding to NaV1.8 channels. This selective interaction at the molecular level enables the drug to target only the specific ion channel subtype responsible for pain, while leaving other channels and physiological systems unaffected, thereby achieving pain relief without CNS or cardiovascular side effects.
Solution Approach 2:
The patent employs parameter changes by systematically modifying chemical parameters of the compound structure (substituent types, positions, and configurations on the quinazoline core) to optimize selectivity for NaV1.8 channels. By adjusting these chemical parameters, the invention achieves a compound that maintains potent inhibition of pain-related sodium channels while minimizing interaction with other targets, thus resolving the contradiction between efficacy and side effects.
2Adaptability or versatility
If non-selective sodium channel blockers are used, then broad pain relief is achieved, but interaction with other channels (hERG, Cytochrome P450, CaV1.2, Kv1.5) increases
Solution Approach 1:
The patent applies segmentation by focusing the therapeutic action on a single, specific target (NaV1.8 channel) rather than broadly blocking multiple channel types. This targeted approach segments the therapeutic effect to only where it is needed for pain relief, eliminating unnecessary interactions with hERG, Cytochrome P450, CaV1.2, and Kv1.5 channels, thereby reducing drug interactions and harmful effects while maintaining effective pain management.
3Object-affected harmful factors
If selective NaV1.8 inhibition is achieved, then side effects are minimized, but pharmacokinetic and pharmacodynamic optimization is required
Solution Approach 1:
The patent employs parameter changes by optimizing various pharmacokinetic and pharmacodynamic parameters of the quinazoline compounds, including absorption, distribution, metabolism, and excretion characteristics. By systematically adjusting chemical parameters and evaluating in vivo performance, the invention achieves compounds that not only selectively inhibit NaV1.8 to minimize side effects but also possess favorable pharmacokinetic properties for clinical translation.
Data Source
AI summary
The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.